Cancer combo trial halted early after enrolling only 5 patients

NCT ID NCT05949632

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 09, 2026 · Last updated Jun 11, 2026 · Updated 1 time

Summary

This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was terminated early after enrolling only 5 people in the UK and EU.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Addenbrookes Hospital

Cambridge, CB2 0QQ, United Kingdom
Beatson West of Scotland Cancer Centrewester

Glasgow, G12 0YN, United Kingdom
Guys Hospital

London, SE1 9RT, United Kingdom
St Bartholomew'S Hospital

London, EC1A 7BE, United Kingdom
The Royal Marsden

London, SW3 6JJ, United Kingdom
The Royal Marsden Nhs Foundation Trust - Sutton

Sutton, SM2 5PT, United Kingdom

Conditions

The condition(s) this trial relates to.

Adenocarcinoma, Mucinous Carcinosarcoma Cystadenocarcinoma, Serous Fallopian Tube Neoplasms Ovarian Neoplasms Uterine Cervical Neoplasms Uterine Neoplasms Vaginal Neoplasms Vulvar Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS